Trial Profile

A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Mar 2023 Results of Pooled Post-hoc analysis , from PERFECT 1 and PERFECT 2 of Safety and Efficacy of Trifarotene 0.005 percent Cream Within the Adolescent Population, presented at the American Academy of Dermatology annual Meeting 2023
07 Apr 2020 Results from PERFECT 1 and PERFECT 2 and NCT02189629 assessing safety and efficacy published in the JAMA: the Journal of the American Medical Association
08 Jan 2020 According to a Galderma media release, Certara's Simcyp based Simulator was used to support U.S. Food and Drug Administration (FDA) new drug application (NDA) for AKLIEF (trifarotene) Cream, 0.005% for the topical treatment of acne.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com